

Kindly amend the application as follows:

IN THE CLAIMS

Kindly amend the claims as follows²:

Please cancel claim 93, 94, 100 and 101 without prejudice.

Please amend claims 69, 74, 76 and 77 as follows:

69. (Three Times Amended) A method for inducing
D/ local tissue formation from a progenitor cell in a mammal comprising the step of implanting in the mammal a morphogenic device at a locus accessible to at least one progenitor cell of the mammal, whereby the morphogenic device induces local tissue formation from the progenitor cell in the mammal, the morphogenic device comprising:

- a) an implantable biocompatible carrier,
 - b) a morphogenic protein disposed in the carrier,
- the morphogenic protein capable of inducing tissue formation when accessible to a progenitor cell, and

1 (...continued)

Brief would be due on October 9, 2002 with a four-month extension of time.

2 An Appendix of Amendments is attached herewith as Exhibit A showing the amendments. In the Appendix, additions are underscored and deletions are bracketed. A copy of the pending claims after entry of this Amendment is also attached herewith as Exhibit B for the Examiner's convenience.

Cost
11

c) a morphogenic protein stimulatory factor (MPSF) selected from the group consisting of IGF-I, hydrocortisone, insulin, and parathyroid hormone, wherein said MPSF is disposed in the carrier, and wherein said MPSF is at a concentration effective to synergistically stimulate the ability of the morphogenic protein to induce tissue formation from the progenitor cell.

72

74. (Three Times Amended) A method of accelerating allograft repair and incorporation in a mammal, comprising the step of implanting at a locus in need of replacement bone a matrix-comprising device, whereby the device accelerates allograft repair and incorporation in the mammal, the device comprising:

- a) an implantable biocompatible carrier,
 - b) a morphogenic protein disposed in the carrier, the morphogenic protein capable of inducing tissue formation when accessible to a progenitor cell, and
 - c) a morphogenic protein stimulatory factor (MPSF) selected from the group consisting of IGF-I, hydrocortisone, insulin, and parathyroid hormone, wherein said MPSF is disposed in the carrier, and wherein said MPSF is at a concentration effective to synergistically stimulate the ability of the morphogenic protein to induce tissue formation from the progenitor cell.
-

76. (Three Times Amended) A method of promoting in vivo integration into a target tissue of a mammal an implantable prosthetic device, the method comprising the steps of:

- a) providing on a surface of the prosthetic device an osteogenic composition, and
- b) implanting the device in a mammal at a locus where the target tissue and the surface of the prosthetic device are maintained at least partially in contact for a time sufficient to permit enhanced tissue growth between the target tissue and the device,

wherein the osteogenic composition comprises (1) an morphogenic protein capable of inducing tissue formation when accessible to a progenitor cell, and (2) a morphogenic protein stimulatory factor (MPSF) selected from the group consisting of IGF-I, hydrocortisone, insulin and parathyroid hormone, wherein said MPSF is at a concentration effective to synergistically stimulate the ability of the morphogenic protein to induce tissue formation from the progenitor cell, and wherein said morphogenic protein and MPSF are disposed on the surface region in an amount sufficient to promote from a progenitor cell enhanced tissue growth between the target tissue and the device.